Research Analysts Offer Predictions for MLTX Q1 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright lowered their Q1 2026 earnings estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.86) for the quarter, down from their prior forecast of ($0.68). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.75) EPS, Q4 2026 earnings at ($0.72) EPS and FY2026 earnings at ($3.10) EPS.

MLTX has been the topic of a number of other research reports. BTIG Research lifted their target price on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. UBS Group set a $24.00 price target on shares of MoonLake Immunotherapeutics in a report on Friday, January 9th. The Goldman Sachs Group downgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and increased their price objective for the company from $8.00 to $10.00 in a research note on Wednesday, January 14th. Zacks Research upgraded shares of MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Needham & Company LLC boosted their target price on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $27.85.

MoonLake Immunotherapeutics Price Performance

MoonLake Immunotherapeutics stock opened at $18.14 on Thursday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 9.27 and a current ratio of 9.27. MoonLake Immunotherapeutics has a 52 week low of $5.95 and a 52 week high of $62.75. The stock has a market capitalization of $1.17 billion, a P/E ratio of -5.15 and a beta of 1.20. The stock has a fifty day moving average of $15.88 and a 200-day moving average of $22.28.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share for the quarter, hitting the consensus estimate of ($0.92). During the same period in the prior year, the firm earned ($0.72) EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MLTX. Kestra Advisory Services LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the fourth quarter worth $26,000. FNY Investment Advisers LLC bought a new stake in MoonLake Immunotherapeutics during the third quarter valued at $28,000. Bank of America Corp DE grew its holdings in MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after acquiring an additional 1,781 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after purchasing an additional 3,166 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in shares of MoonLake Immunotherapeutics by 45.4% during the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after purchasing an additional 1,069 shares in the last quarter. Institutional investors and hedge funds own 93.85% of the company’s stock.

Insider Buying and Selling

In related news, insider Kristian Reich sold 72,908 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total value of $1,052,062.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Da Silva Jorge Santos sold 70,000 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the sale, the chief executive officer directly owned 2,878,577 shares of the company’s stock, valued at $41,710,580.73. This represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 402,908 shares of company stock worth $5,987,162 over the last three months. Insiders own 12.02% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.